Evidence map›Paper›PMID 26287147›Full record

ArticleMolecules (Basel, Switzerland)2015

A Combined Molecular Docking/Dynamics Approach to Probe the Binding Mode of Cancer Drugs with Cytochrome P450 3A4.

Suresh Panneerselvam, Dhanusha Yesudhas, Prasannavenkatesh Durai, Muhammad Ayaz Anwar, Vijayakumar Gosu, Sangdun Choi

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.8field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Anthracycline derivatives inhibit cardiac CYP2J2.Journal of inorganic biochemistry · 2022
    Article
  5. Article
  6. The Multifarious Link between Cytochrome P450s and Cancer.Oxidative medicine and cellular longevity · 2020
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Suresh PanneerselvamDepartment of Molecular Science and Technology, Ajou University, Suwon 443-749, Korea. suresh@ajou.ac.kr.
Dhanusha YesudhasDepartment of Molecular Science and Technology, Ajou University, Suwon 443-749, Korea. dhanusha@ajou.ac.kr.
Prasannavenkatesh DuraiDepartment of Molecular Science and Technology, Ajou University, Suwon 443-749, Korea. prasanna@ajou.ac.kr.
Muhammad Ayaz AnwarDepartment of Molecular Science and Technology, Ajou University, Suwon 443-749, Korea. ayaz@ajou.ac.kr.
Vijayakumar GosuDepartment of Molecular Science and Technology, Ajou University, Suwon 443-749, Korea. gosu@ajou.ac.kr.
Sangdun ChoiDepartment of Molecular Science and Technology, Ajou University, Suwon 443-749, Korea. sangdunchoi@ajou.ac.kr.
Ajou University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cytarabine, daunorubicin, doxorubicin and vincristine are clinically used for combinatorial therapies of cancers in different combinations. However, the knowledge about the interaction of these drugs with the metabolizing enzyme cytochrome P450 is limited. Therefore, we utilized computational methods to predict and assess the drug-binding modes. In this study, we performed docking, MD simulations and free energy landscape analysis to understand the drug-enzyme interactions, protein domain motions and the most populated free energy minimum conformations of the docked protein-drug complexes, respectively. The outcome of docking and MD simulations predicted the productive, as well as the non-productive binding modes of the selected drugs. Based on these interaction studies, we observed that S119, R212 and R372 are the major drug-binding residues in CYP3A4. The molecular mechanics Poisson-Boltzmann surface area analysis revealed the dominance of hydrophobic forces in the CYP3A4-drug association. Further analyses predicted the residues that may contain favorable drug-specific interactions. The probable binding modes of the cancer drugs from this study may extend the knowledge of the protein-drug interaction and pave the way to design analogs with reduced toxicity. In addition, they also provide valuable insights into the metabolism of the cancer drugs.

Indexed as

Molecular Docking SimulationAntineoplastic AgentsCytochrome P-450 CYP3ADrug InteractionsHumansThermodynamicsAntineoplastic AgentsCytochrome P-450 CYP3ACYP450dockingdrug metabolismmolecular dynamics simulation

Identifiers

PMID26287147
PMCPMC6332164
OpenAlexW1818942465

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.